Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Hiroyuki Uchida¹, Gabriella Gobbi², Joseph Zohar³, Allan H Young⁴, Dan Rujescu⁵, Ming-Chyi Huang⁶, Suresh Sundram⁷, Lukoye Atwoli⁸, Jana Vukovic⁹, Kazutaka Ikeda^10,11

¹Department of Neuropsychiatry, Keio University School of Medicine (International College of Neuropsychopharmacology, CINP), Tokyo, Japan.

²Department of Psychiatry, McGill University (CINP), Montreal, Canada.

³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, and National Post-Trauma Center, Sheba Medical Center (CINP), Ramat Gan, Israel.

⁴Department of Brain Sciences, Imperial College London (CINP), London, United Kingdom.

⁵Department of Psychiatry, Medical University of Vienna (CINP), Vienna, Austria.

⁶Taipei City Psychiatric Center, Taipei City Hospital and Department of Psychiatry, Taipei Medical University (CINP), Taipei, Taiwan.

⁷Department of Psychiatry, Monash University (Asian College of Neuropsychopharmacology, AsCNP), Melbourne, Australia.

⁸Medical College East Africa, Aga Khan University (African College of Neuropsychopharmacology, AfCNP), Nairobi, Kenya.

⁹Queensland Brain Institute, The University of Queensland (International Brain Research Organization, IBRO), Brisbane, Australia.

¹⁰National Center of Neurology and Psychiatry (NCNP), CINP, Tokyo, Japan.

¹¹Tokyo Metropolitan Institute of Medical Science (CINP), Tokyo, Japan.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. METHODS: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence, gene…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.